{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"PROK","limit":50},"count":50,"signals":[{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"the potential failure of our clinical trials or our inability to receive regulatory approval for our product candidates; competition with other products; the impact of delays in the commencement, enrollment and completion of our clinical trials; the potential for preliminary results and the results of early-stage trials to not be duplicated in later stage clinical trials; the identification of unacce","filed_date":"2026-03-18","accession":"0001193125-26-113881","full_text":"https://origin.rootz.global/static/filing/0001193125-26-113881.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":88,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. Furthermore, some countries have enacted or are considering enacting legal restrictions on the","filed_date":"2026-03-18","accession":"0001193125-26-113881","full_text":"https://origin.rootz.global/static/filing/0001193125-26-113881.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":25,"context":"the potential failure of our clinical trials or our inability to receive regulatory approval for our product candidates; competition with other products; the impact of delays in the commencement, enrollment and completion of our clinical trials; the potential for preliminary results and the results of early-stage trials to not be duplicated in later stage clinical trials; the identification of unacce","filed_date":"2025-03-17","accession":"0000950170-25-040483","full_text":"https://origin.rootz.global/static/filing/0000950170-25-040483.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":85,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. Furthermore, some countries have enacted or are considering enacting legal restrictions on the","filed_date":"2025-03-17","accession":"0000950170-25-040483","full_text":"https://origin.rootz.global/static/filing/0000950170-25-040483.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":25,"context":"the potential failure of our clinical trials or our inability to receive regulatory approval for our product candidates; competition with other products; the impact of delays in the commencement, enrollment and completion of our clinical trials; the potential for preliminary results and the results of early-stage trials to not be duplicated in later stage clinical trials; the identification of unacce","filed_date":"2024-03-22","accession":"0000950170-24-034946","full_text":"https://origin.rootz.global/static/filing/0000950170-24-034946.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":85,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. 26 Furthermore, some countries have enacted or are considering enacting legal restrictions on","filed_date":"2024-03-22","accession":"0000950170-24-034946","full_text":"https://origin.rootz.global/static/filing/0000950170-24-034946.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":17,"context":"and who vote at the annual meeting, is required for the election of each director . If the number of shares voted FOR a director nominee exceeds the number of votes cast AGAINST, the nominee will be elected as a director. You may vote FOR, AGAINST or ABSTAIN on each of the nominees for election as director. Brokerage firms do not have authority to vote customers unvoted shares held by the firms in street name for the","filed_date":"2023-05-26","accession":"0001140361-23-026831","full_text":"https://origin.rootz.global/static/filing/0001140361-23-026831.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":27,"context":"egulatory approval for our product candidates; • competition with other products; • the impact of COVID-19 on our clinical trials; • the impact of delays in the commencement, enrollment and completion of our clinical trials; • the potential for preliminary results and the results of early stage trials to not be duplicated in later stage clinical trials; • the identi","filed_date":"2023-03-28","accession":"0000950170-23-010324","full_text":"https://origin.rootz.global/static/filing/0000950170-23-010324.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":51,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. Furthermore, some countries have enacted or are considering enacting legal restrictions on the","filed_date":"2023-03-28","accession":"0000950170-23-010324","full_text":"https://origin.rootz.global/static/filing/0000950170-23-010324.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":32,"context":"ite the COVID-19 pandemic to date, we may experience related disruptions in the future that could severely impact our clinical trials, including: | | | | delays or difficulties with patient enrollment in clinical trials; | | | | | | delays, difficulties or a suspension in clinical trial site initiation, including difficulties in recruiting investigators, proceduralists and clinical staff; |","filed_date":"2022-08-26","accession":"0001193125-22-231275","full_text":"https://origin.rootz.global/static/filing/0001193125-22-231275.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":44,"context":"n the import and export of human genetic materials, cells and tissues. Such laws and regulations could impair our ability to import and export human cells and cell-based therapies, which could have a material adverse impact on our business. We cannot predict whether legislative changes will be enacted, whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if","filed_date":"2022-08-26","accession":"0001193125-22-231275","full_text":"https://origin.rootz.global/static/filing/0001193125-22-231275.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":13,"context":"nary shares beneficially owned by them. | | | Name and Address of Beneficial Owner(1) | | ClassAOrdinaryShares | | | ClassBOrdinaryShares | | | % ofTotalVotingPower | | | | Directors and Named Executive Officers | | | | | | Tim Bertram, Ph.D.(2) | | | | | | | 2,696,468 | | | | 1.2 | % | | | Pablo Legorreta(3)(11) | | | | | | | 94,677,968 | | | | 40.8 | % | | | William F. Doyle","filed_date":"2022-08-26","accession":"0001193125-22-231275","full_text":"https://origin.rootz.global/static/filing/0001193125-22-231275.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":32,"context":"ite the COVID-19 pandemic to date, we may experience related disruptions in the future that could severely impact our clinical trials, including: | | | | delays or difficulties with patient enrollment in clinical trials; | | | | | | delays, difficulties or a suspension in clinical trial site initiation, including difficulties in recruiting investigators, proceduralists and clinical staff; |","filed_date":"2022-08-09","accession":"0001193125-22-215250","full_text":"https://origin.rootz.global/static/filing/0001193125-22-215250.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":44,"context":"n the import and export of human genetic materials, cells and tissues. Such laws and regulations could impair our ability to import and export human cells and cell-based therapies, which could have a material adverse impact on our business. We cannot predict whether legislative changes will be enacted, whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if","filed_date":"2022-08-09","accession":"0001193125-22-215250","full_text":"https://origin.rootz.global/static/filing/0001193125-22-215250.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":13,"context":". | | | | | | | | | | | | | | | | Name and Address of Beneficial Owner(1) | | ClassAOrdinaryShares | | | ClassBOrdinaryShares | | | % ofTotalVotingPower | | | | Directors and Named Executive Officers | | | | | | | | | | | | | | | Tim Bertram, Ph.D.(2) | | | | | | | 2,696,468 | | | | 1.2 | % | | | Pablo Legorreta(3)(11) | | | | | | | 94,677,968 | | | | 40.8 |","filed_date":"2022-08-09","accession":"0001193125-22-215250","full_text":"https://origin.rootz.global/static/filing/0001193125-22-215250.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":13,"context":"ons and their interpretation and application may also change from time to time, including as a result of changes in economic, political, social and government policies, and those changes could have a material adverse effect on our business, including our ability to negotiate and complete our initial Business Combination, and results of operations. In addition, a failure to comply with applicable laws or regulations, as","filed_date":"2022-03-24","accession":"0001193125-22-082906","full_text":"https://origin.rootz.global/static/filing/0001193125-22-082906.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":96,"match_count":12,"context":"eeting, and information about ProKidney Corp. that you should consider when you vote your shares are described in the accompanying proxy statement. At the annual general meeting, two persons will be elected to our board of directors. In addition, we will ask stockholders to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024. The boar","filed_date":"2024-04-26","accession":"0001140361-24-022484","full_text":"https://origin.rootz.global/static/filing/0001140361-24-022484.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"tion Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, in increments of 6.25% each calendar quarter following the first anniversary date, or were fully vested upon issuance. On January 17, 2","filed_date":"2023-08-10","accession":"0000950170-23-041374","full_text":"https://origin.rootz.global/static/filing/0000950170-23-041374.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":96,"match_count":12,"context":"Uma Sinha, Ph.D. Dr. Sinha has served on the Board and on the GP Board since the Closing. Dr. Sinha was a member of the SCS Board from September 2021 until the Closing. In April, 2016, Dr. Sinha was appointed the Chief Scientific Officer of BridgeBio Pharma, Inc. (“BridgeBio”) and serves as the Chief Scientific Officer of other BridgeBio subsidiaries, including Eidos Therapeutics. Prior to that, Dr. Sinha served as Chie","filed_date":"2023-04-27","accession":"0000950170-23-015265","full_text":"https://origin.rootz.global/static/filing/0000950170-23-015265.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":93,"match_count":11,"context":"ng clinical trials. Uma Sinha, Ph.D. Dr. Sinha has served on the Board since the Closing. Dr. Sinha was a member of the SCS Board from September 2021 until the Closing. In April, 2016, Dr. Sinha was appointed the Chief Scientific Officer of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq: BBIO) and serves as the Chief Scientific Officer of other BridgeBio subsidiaries, including Eidos Therapeutics. Prior to that, Dr. Sinha served as Chief","filed_date":"2025-03-17","accession":"0000950170-25-040483","full_text":"https://origin.rootz.global/static/filing/0000950170-25-040483.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"from time to time be supplemented or amended by one or more indentures supplemental hereto entered into in accordance with the terms hereof. Interest Payment Date, when used with respect to any installment of interest on a Security of a particular series, means the date specified in such Security or in a Board Resolution or in an indenture supplemental hereto with respect to such series as the fixed","filed_date":"2023-11-22","accession":"0000950103-23-016560","full_text":"https://origin.rootz.global/static/filing/0000950103-23-016560.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"tion Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, in increments of 6.25% each calendar quarter following the first anniversary date, or were fully vested upon issuance. On January 17, 2","filed_date":"2023-11-14","accession":"0000950170-23-063688","full_text":"https://origin.rootz.global/static/filing/0000950170-23-063688.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":84,"match_count":8,"context":"f $10.00 per share, generating aggregate proceeds of $250,000,000 for such Other SCS SPACs. DNAA has not yet consummated a business combination; however, on January26, 2022,DNAA announced that it had entered into a definitive agreement with Akili Interactive Labs, Inc. (Akili). DNAAs transaction with Akili is subject to approval of DNAAs shareholders and other customary closing conditions. Neither DNAB nor DNAD has yet announced or","filed_date":"2022-03-24","accession":"0001193125-22-082906","full_text":"https://origin.rootz.global/static/filing/0001193125-22-082906.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"17 Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, in increments of 6.25% each calendar quarter following the first anniversary date, or were fully vested upon issuance. On January 17, 2","filed_date":"2023-05-11","accession":"0000950170-23-021232","full_text":"https://origin.rootz.global/static/filing/0000950170-23-021232.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"SE 2 PHASE 3 STATUS Pivotal Trial Program Diabetes Type II Prevent/Delay CKD 3/4 006/proact 1 Ongoing 2 (20-50 ml/min/1.73m , N = 600) Diabetes Type II Prevent/Delay CKD 3/4 stratified for SGLT2i Enrollment 016/proact 2 2 (20-44 ml/min/1.73m , N = 600) Mid-2024 Enrollment Long term follow-up study for patients previously treated with REACT 008 4Q 2023 Supportive Trials Diabetes Type II Delay CKD 4/5","filed_date":"2024-01-26","accession":"0001193125-24-015722","full_text":"https://origin.rootz.global/static/filing/0001193125-24-015722.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"l Program PRECLINICAL IND PHASE 1 PHASE 2 PHASE 3 STATUS Lead Platform Programs* Pivotal Trial Program Diabetes Type II Prevent/Delay CKD 3/4 006/proact 1 Ongoing 2 (20-50 ml/min/1.73m , N = 600) Enrollment Diabetes Type II Prevent/Delay CKD 3/4 stratified for SGLT2i 016/proact 2 2 (20-44 ml/min/1.73m , N = 600) Mid-2024 Enrollment Long term follow-up study for patients previously treated with REACT","filed_date":"2023-11-13","accession":"0001193125-23-276225","full_text":"https://origin.rootz.global/static/filing/0001193125-23-276225.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"rogate endpoint in the Phase 3 PROACT 1 study Presented positive Phase 2 REGEN-007 data as a late-breaking clinical trial at American Society of Nephrology (ASN) Kidney Week Generated significant enrollment momentum in the Phase 3 PROACT 1 study Initiated expansion of ProKidney’s in-house manufacturing footprint in two adjacent, company-owned manufacturing facilities totaling 180,000 SF in Win","filed_date":"2026-02-02","accession":"0001193125-26-033594","full_text":"https://origin.rootz.global/static/filing/0001193125-26-033594.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"a806e210803340437c **Words:** 4,314 --- EX-99.1 2 prok-ex99_1.htm EX-99.1 Exhibit 99.1 ProKidney Reports Full Year 2025 Financial Results and Business Highlights • On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 • In a July 2025 Type B meeting, aligned with FDA on the acc","filed_date":"2026-03-18","accession":"0001193125-26-113893","full_text":"https://origin.rootz.global/static/filing/0001193125-26-113893.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"ing eGFR slope as the surrogate endpoint Presented positive Phase 2 REGEN-007 data as a late-breaking clinical trial at American Society of Nephrology (ASN) Kidney Week 2025 Generated significant enrollment momentum in the Phase 3 PROACT 1 study; pivotal Phase 3 readout of surrogate endpoint anticipated in Q2 2027 Initiated expansion ProKidney’s in-house manufacturing footprint in two adjacent","filed_date":"2026-01-12","accession":"0001193125-26-009807","full_text":"https://origin.rootz.global/static/filing/0001193125-26-009807.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"d our plans for manufacturing and organizational development as we progress toward potential commercialization,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney. “Patient enrollment in proact 1 continues according to plan and we target interim data by year end 2024. In addition, we recently completed enrollment in REGEN-007 with a total of 53 subjects randomized into this ope","filed_date":"2023-05-11","accession":"0000950170-23-021256","full_text":"https://origin.rootz.global/static/filing/0000950170-23-021256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"(15% of U.S. Adult Population) REACT: REnal Autologous Cell Therapy for CKD Advancing a comprehensive clinical plan to demonstrate commercial potential REACT Phase 3 DKD Trials proact 1: Ongoing enrollment in U.S., Canada, and EU; Interim anticipated YE24 proact 2: 1H23 ROW enrollment; Interim anticipated by YE25 Global Phase 3 blinded, sham-controlled trials to establish safety & efficacy of REACT","filed_date":"2023-03-06","accession":"0000950170-23-006251","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006251.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"va2lkbmV5LmNvbQ/images/2025-04-04_logo.png --- EX-99.1 2 prok-ex99_1.htm EX-99.1 Exhibit 99.1 ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights • Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 • On track for","filed_date":"2026-08-10","accession":"0001193125-26-342397","full_text":"https://origin.rootz.global/static/filing/0001193125-26-342397.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"17, 2022 with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, in increments of 6.25% each calendar quarter following the first anniversary date, or were fully vested upon issuance. 23 Upon consumma","filed_date":"2026-08-10","accession":"0001193125-26-342373","full_text":"https://origin.rootz.global/static/filing/0001193125-26-342373.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"tion Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, in increments of 6.25% each calendar quarter following the first anniversary date, or were fully vested upon issuance. On January 17, 2","filed_date":"2025-08-12","accession":"0000950170-25-107352","full_text":"https://origin.rootz.global/static/filing/0000950170-25-107352.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"ion vests subject to the achievement of both time and performance vesting conditions, with 25% of the shares vesting on November 15, 2024 and the remaining shares vesting in equal quarterly installments over the following three years, subject to the achievement of certain performance milestones. | | | (3) | The option vests 25% on November 15, 2024 and the remaining 75% vests in substantial","filed_date":"2024-04-26","accession":"0001140361-24-022484","full_text":"https://origin.rootz.global/static/filing/0001140361-24-022484.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"hs ended September 30, 2022, the Company granted 129,370 stock option awards under the 2022 Plan. The weighted average grant date fair value of these awards was $7.15. These awards vest in equal installments upon the anniversary of grant over a period of three years. As of September 30, 2022, the unrecognized compensation expense related to these awards was $910,000. The following table summarizes t","filed_date":"2022-11-14","accession":"0000950170-22-024794","full_text":"https://origin.rootz.global/static/filing/0000950170-22-024794.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"tion Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, in increments of 6.25% each calendar quarter following the first anniversary date, or were fully vested upon issuance. On January 17, 2","filed_date":"2025-11-10","accession":"0001193125-25-274303","full_text":"https://origin.rootz.global/static/filing/0001193125-25-274303.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"tion Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, in increments of 6.25% each calendar quarter following the first anniversary date, or were fully vested upon issuance. On January 17, 2","filed_date":"2024-11-12","accession":"0000950170-24-125312","full_text":"https://origin.rootz.global/static/filing/0000950170-24-125312.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"Congenital Anomalies – Prevent/Delay (14-50 ml/min/1.73m2, N= 5) Fully Enrolled Trial Completed Fully Enrolled US/OUS 2H2023 Enrolling 007 006/proact 1 015 004 003 002 Trial Completed 008 Enrollment 3Q2023 016/proact 2 Enrolling Unilateral injections bilateral injections Frozen product PROKIDNEY 12 Building a Comprehensive Data Package Clinical program designed to expand potential patient pop","filed_date":"2023-09-11","accession":"0000950170-23-047359","full_text":"https://origin.rootz.global/static/filing/0000950170-23-047359.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"PFV) 2H 22 Additional interim data 2022 Initial evaluation data1 Diabetic CKD 4/5 (15-20 ml/min/1.73m2) 2023 CSR REACT/CAKUT Congenital Anomalies of Kidney and Urinary Tract (CAKUT) 2022 Complete enrollment; Additional interim data Additional Platform Programs (Research) Optimize Preclinical IND Phase 1 Phase 2 Phase 3 Registration (BLA/MAA) REACT/Gen Genetic Kidney Disease (PCKD) - Prevent REACT/Uni","filed_date":"2022-01-18","accession":"0001193125-22-010520","full_text":"https://origin.rootz.global/static/filing/0001193125-22-010520.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":36,"match_count":2,"context":"with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. A failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business, including our ability to negotiate and complete our initial Business Combination, and results of operations. In addition, those laws and regulations and their interpretation and appl","filed_date":"2022-05-16","accession":"0001193125-22-151998","full_text":"https://origin.rootz.global/static/filing/0001193125-22-151998.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"tion Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, in increments of 6.25% each calendar quarter following the first anniversary date, or were fully vested upon issuance. On January 17, 2","filed_date":"2025-05-12","accession":"0000950170-25-069251","full_text":"https://origin.rootz.global/static/filing/0000950170-25-069251.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"tion Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, in increments of 6.25% each calendar quarter following the first anniversary date, or were fully vested upon issuance. On January 17, 2","filed_date":"2024-08-09","accession":"0000950170-24-094732","full_text":"https://origin.rootz.global/static/filing/0000950170-24-094732.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":32,"match_count":4,"context":", we filed a protocol Effective June 1st, we restarted manufacturing amendment with the FDA in March, 2024; Central for our clinical studies IRB approval has been received; sites are now open for enrollment under the amended protocol We anticipate QP Declaration of Equivalence to EU GMPs to be received by the end of June In our PROACT 2 study, we initiated sites in Spain in 2024 anticipation of recei","filed_date":"2024-06-10","accession":"0001193125-24-157913","full_text":"https://origin.rootz.global/static/filing/0001193125-24-157913.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"tion Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, in increments of 6.25% each calendar quarter following the first anniversary date, or were fully vested upon issuance. On January 17, 2","filed_date":"2024-05-10","accession":"0000950170-24-057785","full_text":"https://origin.rootz.global/static/filing/0000950170-24-057785.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"completed and was submitted to the FDA in late March. This amendment updated the protocol to focus on patients with higher risk of kidney failure. In the PROACT 1 Phase 3 clinical study, the eGFR enrollment range will be modified from the current range of ≥ 20 to ≤ 50 ml/min/1.73m2 to a new range of ≥ 20 to ≤ 35 ml/min/1.73m2. The Company believes that focusing on patient","filed_date":"2024-05-10","accession":"0000950170-24-057443","full_text":"https://origin.rootz.global/static/filing/0000950170-24-057443.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"idney Disease (CKD) PROKIDNEY 3 REACT: REnal Autologous Cell Therapy for CKD Advancing a comprehensive clinical plan to demonstrate commercial potential REACT Phase 3 DKD Trials proact 1: Ongoing enrollment in U.S., Canada, and EU; Interim anticipated YE24 proact 2: 1H23 ROW enrollment; Interim anticipated by YE25 Global Phase 3 blinded, sham-controlled trials to establish safety & efficacy of REACT","filed_date":"2023-01-10","accession":"0000950170-23-000572","full_text":"https://origin.rootz.global/static/filing/0000950170-23-000572.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":26,"match_count":2,"context":"future relationship between the United States and other countries with respect to trade policies, treaties and tariffs. These developments, or the perception that any of them could occur, may have a material adverse effect on global economic conditions and the stability of global financial markets, and may 30 significantly reduce global trade and, in particular, trade between the impacted nations and the United States","filed_date":"2025-05-12","accession":"0000950170-25-069251","full_text":"https://origin.rootz.global/static/filing/0000950170-25-069251.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":26,"match_count":2,"context":", 2027. Other Global Developments In 2022, various central banks around the world (including the Federal Reserve in the United States) raised interest rates. While these rate increases have not had a significant adverse impact on the Company to date, the impact of such rate increases on the overall financial markets and the economy may adversely impact the Company in the future, including by making capital more difficult a","filed_date":"2023-11-14","accession":"0000950170-23-063688","full_text":"https://origin.rootz.global/static/filing/0000950170-23-063688.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROK","company":"PROKIDNEY CORP.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":26,"match_count":2,"context":", 2027. Other Global Developments In 2022, various central banks around the world (including the Federal Reserve in the United States) raised interest rates. While these rate increases have not had a significant adverse impact on the Company to date, the impact of such rate increases on the overall financial markets and the economy may adversely impact the Company in the future, including by making capital more difficult a","filed_date":"2023-08-10","accession":"0000950170-23-041374","full_text":"https://origin.rootz.global/static/filing/0000950170-23-041374.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"5ec9cb20deb8d271784196e9ff4072b5686706cc953dac94caa88ffe3a5fefc5","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"e765759806f85fa9dd1ec721a7d0f8716254046ab0187122906b42b2eba80754","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":1,"hourly_limit":500,"remaining":499,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}